SPECT/CT PROSTASCINT imaging guides prostate cancer therapy
SPECT/CT images of PROSTASCINT, a monoclonal antibody attached to the radioisotope Indium-111 for specific targeting of prostate-specific membrane antigen, helped identify areas that needed increased doses of radioactive seeds in patients at risk for metastatic prostate cancer. The images also helped in evaluating for biochemical disease-free survival by showing the presence or absence of lymph node metastases.
Reuters | 11/04
This story published in SNM SmartBrief on 11/05/2009
More from SmartBrief:
FCH-PET/CT identifies bone metastases in prostate cancer patients
Friday, October 9, 2009
Combined methods could help improve prostate cancer diagnosis
Tuesday, October 6, 2009
Research: PET, gene could help improve prostate cancer management
Monday, October 5, 2009
Get stories like these delivered daily for FREE:
|
SNM SmartBrief
Designed specifically for nuclear medicine and molecular imaging professionals, SNM SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news and information to save you time and keep you informed on our profession. Learn more |
|